Ulisse Biomed SpA
UBM
Company Profile
Business description
Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.
Contact
Area Science Park - SS14 km.163, 5
Basovizza34149
ITASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.80 | 20.60 | -0.22% |
| CAC 40 | 7,707.90 | 4.00 | 0.05% |
| DAX 40 | 24,037.33 | 135.12 | 0.57% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,196.34 | 9.00 | 0.10% |
| HKSE | 25,617.42 | 539.80 | 2.15% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 42,188.79 | 529.68 | -1.24% |
| NZX 50 Index | 13,070.45 | 139.72 | 1.08% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,927.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,875.53 | 17.60 | 0.46% |